Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with.HEAL-101 at ESGCT 2026
Filed with Euronext · · 3 pages · English
Story so far
- Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
- Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
- Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications
Earlier from Cellectis
- Monthly information on share capital and company voting rights
- Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
- Cellectis annonce sa transformation stratégique en société d'édition du génome in vivo
- Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
- Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Follow Cellectis into a list and get an email when it puts out news.
Follow Cellectis